Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CJRB-101 with Pembrolizumab in Advanced Cancer
NCT05877430Phase 2Recruiting
- Sponsor
- CJ Bioscience
- Start
- Sep 2023
- Primary completion
- Jul 2026
- Modality
- Live Biotherapeutic Products
- Countries
- 2
01
Overview
A Phase 2 trial of CJRB-101 in non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), melanoma, sponsored by CJ Bioscience. Started Sep 2023; status: recruiting.
02
Drugs
CJRB-101
03
Conditions
non-small cell lung cancer (NSCLC)head and neck squamous cell carcinoma (HNSCC)melanoma
Beyond the preview
Go deeper on NCT05877430.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05877430.